Journal of pain and symptom management
-
J Pain Symptom Manage · Jan 2024
Multicenter StudyCancer Pain Management in Patients Receiving Inpatient Specialized Palliative Care Services.
Cancer pain is a common complication that is frequently undertreated in patients with cancer. ⋯ SPC achieved cancer pain management over a short period with a high level of patient satisfaction resulting in significant pain reduction and few documented adverse events.
-
J Pain Symptom Manage · Jan 2024
Randomized Controlled TrialManaging Symptom Distress: Key Factors for Patients on Adjuvant Endocrine Therapy for Breast Cancer.
Patients with breast cancer taking adjuvant endocrine therapy (AET) experience significant symptoms impacting mood, quality of life (QOL), and AET adherence and satisfaction. ⋯ Coping skills may buffer the effect of AET symptom distress. Findings indicate the relationship between symptom distress and self-efficacy is more nuanced and requires further research to better understand.
-
J Pain Symptom Manage · Jan 2024
Randomized Controlled TrialPatient Controlled Subcutaneous Analgesia of Hydromorphone Versus Morphine to Treat Moderate and Severe Cancer Pain: A Randomized Double-Blind Controlled Trial.
Hydromorphone and morphine are the common drugs used for the treatment of moderate to severe cancer pain. Patient controlled subcutaneous analgesia (PCSA) is an effective technique to manage cancer pain. However, few studies have been conducted to show the efficacy and safety of PCSA of hydromorphone for the relief of cancer pain. ⋯ This study found that the PCSA of both hydromorphone and morphine could effectively and safely relieve short-term moderate to severe cancer pain. Of note, the PCSA of hydromorphone took effect more quickly than that of morphine.
-
J Pain Symptom Manage · Jan 2024
Randomized Controlled TrialImpact of Dosing and Duration of Dexamethasone on Serious Corticosteroid-Related Adverse Events.
Corticosteroids are commonly prescribed in oncology, but few studies have examined its adverse events (AEs) compared to placebo control. ⋯ Greater dexamethasone exposure, even at moderate doses, was associated with more serious AEs. Prescribers should cautiously weigh the risks and benefits of dexamethasone use, especially when considering for palliation of symptoms.